NeoGenomics Announces Launch of NEO PanTracer LBx
NeoGenomics Inc., a leader in oncology diagnostic solutions dedicated to advancing precision medicine, has announced the release of NEO PanTracer LBx. This new blood-based comprehensive genomic profiling assay expands NeoGenomics' PanTracer lineup.
About the PanTracer LBx
The PanTracer LBx is a minimally invasive liquid biopsy that leverages circulating tumor DNA to assist in selecting appropriate therapies, matching patients to clinical trials, and monitoring disease progression over time. It is particularly useful when tumor tissue samples are limited or inaccessible.
CEO Remarks
Tony Zook, CEO of NeoGenomics, stated, "Introducing our liquid biopsy test positions us at the cutting edge of precision oncology. As the need for quicker, less invasive, and more readily available genomic testing grows, PanTracer LBx broadens our market reach, strengthens our clinical offerings, and opens new revenue opportunities in therapy guidance, clinical trial matching, and disease surveillance. This milestone highlights our dedication to sustainable growth and leadership in cancer diagnostics."